MHRA Updates Botulinum Toxin Warnings: Medico-Legal Implications for Aesthetic Practitioners
In July 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) issued updated safety advice regarding botulinum toxin type A following reports of iatrogenic botulism after therapeutic and cosmetic use.
Iatrogenic botulism is rare, but potentially serious. It can occur when the effects of botulinum toxin extend beyond the intended treatment area, with symptoms including difficulty swallowing, slurred speech, breathing difficulties and muscle weakness. The MHRA advises that symptoms typically occur between four and eight days following treatment, although they may take up to four weeks to develop.
The updated guidance is important from a patient safety perspective, but it also raises some relevant medico-legal considerations for practitioners working in non-surgical aesthetics.
When I review cases as an Aesthetic Expert Witness, one distinction is particularly important: a complication is not, in itself, evidence of negligence, because medicine carries risk. A patient can experience a recognised complication despite receiving appropriate treatment from a competent practitioner. The question in a clinical negligence case is therefore not simply whether something went wrong, but if the care provided met the appropriate standard. The latest MHRA guidance provides an opportunity to consider what that may involve in relation to botulinum toxin.
Patient assessment before treatment
The MHRA identifies several circumstances in which the risk of adverse reactions from toxin spread or botulism may be increased. These include certain underlying neurological conditions, a history of dysphagia or aspiration, higher doses of botulinum toxin, treatment outside licensed indications or approved sites, and the use of counterfeit or unauthorised products.
A practitioner should have an appropriate understanding of the patient's medical history, current medication and any relevant conditions before deciding if treatment is suitable. The clinical record should demonstrate that relevant information was obtained and considered, not simply recording that a consultation took place.
In a medico-legal review, documentation can become significant. Months or years after treatment, recollection is unlikely to provide the same level of evidence as a contemporaneous clinical record.
Consent and a rare complication
The updated warning also has implications for informed consent.
The fact that a complication is rare does not automatically make it irrelevant to the consent process. What matters is if the risk is material to the individual patient and if there are reasonable alternatives that should be discussed. Consent should give a patient enough information to make an informed decision about wishing or not wishing to proceed. It should also be specific to the treatment, not a standard consent form.
The MHRA is strengthening the product information for UK-authorised botulinum toxin type A products to highlight iatrogenic botulism and the need to seek immediate medical attention if symptoms occur. Practitioners should therefore consider if their own consent information and patient literature remain consistent with current regulatory advice.
Unauthorised products
One of the main messages within the MHRA update concerns counterfeit and unauthorised botulinum toxin products. Botulinum toxins are prescription-only medicines in the UK. The MHRA has been investigating the illegal sale and supply of unlicensed and counterfeit products following a spike in hospital admissions reported last year.
From a medico-legal perspective, knowing exactly what was administered is fundamental. Records should clearly identify the product used and contain the appropriate information necessary for traceability. Practitioners should also be satisfied that medicines have been obtained through legitimate supply routes.
The MHRA additionally reminds healthcare professionals that botulinum toxin units are not interchangeable between products. Each authorised product has its own guidance concerning indications, administration sites and dosing. These details may become highly relevant when considering if treatment was appropriately planned and administered in a possible future case.
Aftercare
Patients are being advised to seek immediate medical attention if they experience symptoms suggestive of botulism, including difficulty swallowing, slurred speech or breathing difficulties. For that advice to be useful, patients need to have received it.
Appropriate safety-netting should explain what a patient might reasonably expect after treatment, which symptoms warrant contacting the practitioner and which require urgent medical assessment. There should also be an appropriate pathway for responding when a patient does report a concerning symptom.
When reviewing a case involving a complication, the care provided after the initial procedure can be just as relevant as the procedure itself. Were the patient's concerns taken seriously? Was appropriate advice given? Was escalation required? If so, did it happen promptly?
A technically competent injection does not represent the entirety of the practitioner's duty of care.
Known complication or negligent care?
If a patient develops iatrogenic botulism following botulinum toxin treatment, the occurrence of the condition alone does not tell us that there has been a breach of duty.
A medico-legal assessment would need to consider the wider circumstances: patient selection, medical history, consent, the product administered, dose and injection sites, prescribing arrangements, documentation, aftercare and the response to developing symptoms.
Describing an adverse event as a "known complication" does not automatically answer questions about the standard of care. Known risks still need to be communicated and managed appropriately.
Regulatory updates such as this one are relevant beyond the immediate safety warning. They contribute to the body of information practitioners are expected to remain aware of and should prompt clinics to review their policies, consent processes, patient information and complication pathways.
For patients, these standards provide protection. For practitioners, they provide a guideline for defensible clinical decision-making. And when care is subsequently examined from a medico-legal perspective, it is often the quality of those decisions, rather than the outcome alone, that becomes most important.